Clinical Trial Network, LLC

1. Eisai Inc. $439,787 238 payments
2. AstraZeneca Pharmaceuticals LP $381,125 14 payments
3. E.R. Squibb & Sons, L.L.C. $292,395 8 payments
4. Organon LLC $237,313 35 payments
5. Ipsen Innovation $209,777 206 payments
6. Bausch Health US, LLC $199,819 128 payments
7. AbbVie, Inc. $13,465 2 payments
8. Ascendis Pharma, Inc. $11,000 1 payment

1. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $410,034 235 payments
2. a randomised,double blind,placebo controlled study to evaluate cortisol reserve in response to adrenocorticotropic hormone stimulation test following treatment with baxdrostat for eight weeks in participants with ucontrolled hypertension $275,601 3 payments
3. Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) $199,819 128 payments
4. Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants $122,573 101 payments
5. An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $106,309 2 payments
6. A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants $87,204 105 payments
7. Og-8175A-023 $81,079 11 payments
8. Og-8175A-023 $80,953 8 payments
9. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease $79,917 2 payments
10. A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA $47,575 3 payments

1. Patient care $237,313 35 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.